2024 / Two randomized, double-blind phase III trials
Studying the upper face as a whole.
What is established by ULTRA I and II?
Source access: publication abstract
The study#
- Design
- Two randomized, double-blind phase III trials
- Population
- 362 and 368 participants
- Follow-up / endpoint
- Day 30 plus open-label extensions
- Source
- Aesthetic Surgery Journal · PMID 39475143
What the authors found#
IncobotulinumtoxinA outperformed placebo on the prespecified upper-facial-line endpoints in both studies.[1]
Editorial interpretation
Why it is interesting#
The programme addresses simultaneous treatment of multiple upper-face regions.
Keep the randomized period separate from the extension when assessing certainty.
What it cannot tell us#
- Placebo comparisons do not rank commercial toxin brands.
- Open-label extension results have different protection against bias from the blinded phase.
Selection for this library reflects educational interest. It is not a systematic search, formal certainty grade, or complete account of the literature.
Funding & commercial context#
Consult the publication's full text for funding and conflict-of-interest statements; the abstract does not provide a complete disclosure.
Continue with the product
Source & citation#
IncobotulinumtoxinA — ULTRA I and ULTRA II ↗Checked 2026-09-06 · Aesthetic Surgery Journal · PMID 39475143. Cite the original publication when discussing its results; this page is an interpretation.
Aesthetic Pass. Studying the upper face as a whole. Product Atlas research interpretation 2026.09.06.1. https://aestheticpass.com/products/studies/incobotulinumtoxin-ultra/